DMD and Duchenne muscular dystrophy: An initial phase 2, randomized, 24-week clinical trial that evaluated the efficacy, safety, and tolerability of viltolarsen in boys 4 to < 10 years of age with DMD demonstrated muscle dystrophin production [13].